We compared the safety and efficacy of haploidentical stem cell transplantation (haplo-SCT) to matched donor SCT (matched-SCT) in treating hematological malignancies. The Medline, Cochrane, EMBASE, and Google Scholar databases were searched through 21 June 2017 using the search term "(hematological disease) AND matched AND (haploidentical OR haplo-identical OR haplo identical OR haplo transplantation OR haplo transplant OR haplo-SCT OR haplo-HSCT OR haplo-HCT)." Twenty-five studies enrolling 11,359 patients (haplo-SCT: 2677; matched-SCT: 8682) were included. The primary outcomes were acute and chronic graft-versus-host disease (GVHD), non-relapse mortality, and 1-year cumulative incidence of relapse. Haplo-SCT was associated with similar risks as matched-SCT for all primary endpoints. Subgroup analysis of patients who received a matched-SCT from a related donor revealed that patients who received haplo-SCT had a lower risk of acute GVHD. Among patients who received reduced-intensity conditioning (RIC), those who received haplo-SCT had a higher risk of acute grade II-IV GVHD and non-relapse mortality than did patients who received a matched-SCT from a related or unrelated donor. Haplo-SCT should continue to be considered as a safe and effective transplant option when a matched donor is unavailable, but it may not be suitable for patients who receive RIC.
Introduction
Hematological malignancies (HMs) are a diverse group of cancers that are associated with substantial incidence and mortality in all regions of the world. Non-Hodgkin lymphoma (NHL) is the eighth most prevalent cancer worldwide [1, 2] . Chronic lymphoid leukemia (CLL), acute myeloid leukemia (AML), acute lymphoid leukemia (ALL), multiple myeloma (MM), Hodgkin lymphoma (HL), and chronic myeloid leukemia (CML) rank 21st, 22nd, 25th, 26th, 28th, and 30th, respectively in the Global Burden of Cancer report [2] . While NHL is the most prevalent type of HA, others may cause a larger burden of disease. Collectively, the leukemias are associated with two times more disability-adjusted life years (DALYs) than NHL and ten times more DALYs than HL. AML is ranked 22nd for incidence but 15th for total number of deaths [2] . Among a group of patients in the Danish Cancer Register, disability pension was received by more patients with MM than with HL or acute and chronic leukemia [3] . Studies of large national and international registries also indicate that both MM and AML are associated with poor survival relative to other types of HMs [4, 5] . Encouragingly, analysis of These authors contributed equally: Bo Yang, Ruili Yu, Lili Cai.
* Peifeng He hepeifeng2006@126.com * Xuechun Lu luxuechun@126.com several decades' worth of data contained in the EURO-CARE registry reveals that survival has increased for most types of HMs. However, improvements are not uniform, with 5-year survival of CML improving by almost 20% between the late 1990s to the late 2000s but that of AML improving by only 2%. In addition, survival of patients with myelodysplastic syndrome (MDS) may not have increased at all [4] . The CONCORD-2 study determined that survival of adult leukemia also varies substantially by country, and worldwide improvement has been non-uniform during the past 10 years [6] . These statistics highlight the need for more accessible and successful treatment options for HMs. An increasing number of patients with an HM are benefitting from a hematopoietic stem cell transplant (SCT), with the number of SCTs rising by more than 20% over the past 10 to 12 years in Europe, Australia, New Zealand, and China [7] [8] [9] . While chemotherapy is the mainstay of first-line therapy to induce remission, SCT is routinely used not only to induce remission in patients with relapsed or refractory disease, but also to consolidate remission in patients who have responded to chemotherapy [10] [11] [12] . Successful outcomes after SCT depend heavily on the degree of donor-recipient matching at the human leukocyte antigen (HLA) loci; a poorly matched transplant will trigger graftversus-host disease (GVHD) and increase mortality [13, 14] . Given these issues, HLA-matched donors have been and continue to be the preferred choice for SCT [15] [16] [17] . However, recent studies have documented a substantial lack of matched donors for many patients, particularly those who are not Caucasian [18] [19] [20] [21] . As a result, the use of donors who are not matched at all classic HLA loci (HLA-A, -B, -C, DRB1, and DQB1) will continue to increase.
An HLA-haploidentical donor is one type of mismatched donor available to patients requiring an SCT. These donors are siblings or other family members of the patient who are matched at all HLA loci on one chromosome. Matching is a result of inheritance of a large contiguous stretch of DNA on chromosome 6. Therefore, the degree of mismatch of haploidentical donors (at least 50%) is usually substantially less than that of a matched donor, and haplo-SCT may result in significant GVHD and a host-versus-graft response, which could result in rejection of the transplanted cells [22] . In spite of the risk of complications, the use of haplo-SCT greatly increases the pool of available donors for many patients because most have family members who are a potential match. Additional advantages of haplo-SCT include the possibility of finding a donor more quickly and the potential for lower costs, as some studies have found an association between higher costs and transplants from unrelated donors [23] [24] [25] . For these reasons, the use of haplo-SCT has jumped substantially over the past 10 to 12 years, growing by almost 300% among patients in Europe and China [7] . Notably, in the United States in 2015, haplo-SCT was only 8% of allogeneic SCT among all patients, but 18% of all autologous and allogeneic SCT among AfricanAmerican patients [26] . Given that the availability of haplo-SCT is allowing many more patients to receive a transplant, additional data are needed to understand how the safety of this procedure compares to that of allogeneic SCT from a matched donor. This will ensure that patients and caregivers have the information they need to decide whether to proceed with a haplo-SCT or wait for a matched donor. To shed light on this issue, we performed a meta-analysis to compare safety and efficacy of haplo-SCT to matched donor SCT (matched-SCT) from a related or unrelated donor.
Methods

Search strategy and selection criteria
We searched the Medline, Cochrane, EMBASE, and Google Scholar databases through 21 June 2017 with the search term "(hematological disease) AND matched AND (haploidentical OR haplo-identical OR haplo identical OR haplo transplantation OR haplo transplant OR haplo-SCT OR haplo-HSCT OR haplo-HCT)." The reference lists of relevant studies were also hand-searched. The inclusion criteria were as follows: (1) The study enrolled patients with hematological malignancies who received either a haplo-SCT or a matched-SCT from a related donor (MRD) or an unrelated donor (MUD); (2) the study was a randomized controlled trial, a prospective study, a retrospective study, or a two-arm study; and (3) the study reported a quantitative outcome of interest. Exclusion criteria were the following: (1) study results were reported in a letter, comment, editorial, case report, proceeding, or personal communication; and (2) the study did not report a quantitative outcome of interest. Meta-analyses do not involve human subjects and do not require Institutional Review Board review.
Study selection and data extraction
The search for studies was performed by two independent reviewers. Any uncertainty regarding eligibility was resolved by consulting a third reviewer. The search strategy used a two-step process. First, the titles and abstracts of all articles identified in the database search were compared against the inclusion and exclusion criteria. Articles meeting the inclusion criteria and not meeting the exclusion criteria were selected for the second step of the search process. In this step, the full text of the article was examined to determine if it met all of the inclusion criteria and none of the exclusion criteria. Those that did were included in the systematic review and meta-analysis. The following information was extracted from the included studies: the name of the first author, year of publication, study design, type of disease, disease risk index, type of transplant, number of participants in each group, type of conditioning regimen, length of follow-up, and major outcomes. The disease risk index was previously used by Armand et al. [27, 28] .
Quality assessment
We utilized the Quality In Prognosis Studies (QUIPS) tool to assess any publication bias of the included studies [29] . This tool evaluates the bias of six domains of a study: study participation, study attrition, prognostic factor measurement, outcome measurement, study confounding, and statistical analysis and reporting. Green indicates a low risk of bias, red indicates a high risk of bias, and yellow indicates that risk of bias is uncertain. The QUIPS tool can be used to determine the bias of individual studies and to summarize the collective bias of all studies included in a meta-analysis.
Outcome measures
The primary outcomes of this study were acute GVHD, chronic GVHD, non-relapse mortality, and 1-year cumulative incidence of relapse (CIR).
Statistical analysis
Continuous data are presented as the mean; dichotomous and categorical data are presented as number and percent. For each outcome with dichotomous variables, we calculated the odds ratios (ORs) with 95% confidence intervals (CIs) for each individual study and for all the studies combined to compare patients who underwent haplo-SCT and matched-SCT. An OR of >1 indicated that the haplo-SCT group had less risk than the matched-SCT group. An OR of <1 indicated that the haplo-SCT group had higher risk than the matched-SCT group. A χ2-based test of homogeneity was performed, and the Cochran's Q and inconsistency index (I 2 ) statistics were determined. A random-effects model was used if the I 2 statistic was >50%, which indicated heterogeneity between studies. Otherwise, a fixed-effect model was used. Pooled effects were calculated and a two-sided P value of <0.05 indicated statistical significance. Subgroup analyses were performed with the following populations of patients: (1) MRD, compared patients who received a haplo-SCT to those who received a matched-SCT from an MRD; (2) MUD, compared patients who received a haplo-SCT to those who received a Records after duplicates removed (n = 624)
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matched-SCT from a MUD; (3) MA, compared patients who received a haplo-SCT with an MA regimen to those who received a matched-SCT with an MA regimen; (4) reduced-intensity conditioning (RIC), compared patients who received a haplo-SCT with an RIC regimen to those who received a matched-SCT with an RIC regimen; and (5) acute leukemia, compared patients with acute leukemia who received a haplo-SCT to patients with acute leukemia who received a matched-SCT. A sensitivity analysis was carried out to determine if any one study had a disproportionate impact on the pooled effect. The leave-one-out approach was used to calculate a pooled effect with all studies but one. With this approach, if the pooled effect does not change in direction or significance, then the individual effect does not unduly influence the pooled effect. In addition, study heterogeneity and publication bias were assessed by constructing funnel plots (if there were more than 10 studies included in the analysis [30] ). The absence of bias is indicated by the data points forming a symmetric funnel-shaped distribution on the funnel plot. All analyses were performed by using the Comprehensive Meta-Analysis statistical software, version 2.0 (Biostat, Englewood, NJ, USA).
Results
Search results
A summary of our search process is shown in Fig. 1 . Searching the Medline, Cochrane, EMBASE, and Google Scholar databases through 21 June 2017 with the search term "(hematological disease) AND matched AND (haploidentical OR haplo-identical OR haplo identical OR haplo transplantation OR haplo transplant OR haplo-SCT OR haplo-HSCT OR haplo-HCT)" identified 730 citations. An additional 25 were identified by other sources. After screening the titles and abstracts, we discarded 516 articles. Of the remaining 108 articles that underwent full-text review, 84 were excluded for the following reasons: the study objective was not consistent with the purpose of a meta-analysis (n = 76) or the study did not report an outcome of interest (n = 8). The remaining 24 articles fulfilled all of the eligibility criteria and were included in this review and meta-analysis .
Systematic review
Of the 24 studies, 19 were retrospective and 5 were prospective. Of these 5 prospective studies, 3 assigned donors based on availability and 1 used an algorithm to assign donors to a first (matched sibling), second (matched unrelated donor), or third (partially matched family member) choice. We were unable to determine how the fifth study assigned donors. The 24 studies enrolled a total of 11,359 patients: 2677 in the haplo-SCT group and 8682 in the matched donor SCT group. The number of patients in each arm ranged from 28 to 372 patients for the haplo-SCT arm and from 23 to 2490 for the matched-SCT arm. The 24 studies made18 comparisons of haplo-SCT to a matched-SCT from an MRD (2586 patients; 30% of all matched-SCT patients) and 13 to a matched-SCT from a MUD (6096 patients; 70% of all matched-SCT patients). Among patients in the haplo-SCT group, 1569 (59%) were enrolled in a study that compared haplo-SCT to matched-SCT from a MUD and 1905 (71%) were in a haplo-SCT group that was compared to matched-SCT from an MRD.
The patient demographics and clinical characteristics are summarized in Table 1 . Among studies that enrolled children, adolescents, or adults (8 studies), the mean or median ages of the treatment groups ranged from 3 to 59 years. Among studies that enrolled only adults (15 studies), the ages ranged from 26 to 63 years. Most of the studies (13 of the 23 reporting summary data) did not have treatment arms that were well matched with respect to age, with the difference in mean or median age being more than 5 years. The proportion of patients who were male ranged from 17 to 77%. Although the length of follow-up ranged from 13 to 67 months, only 6 studies reported a follow-up of more than 45 months. For half of the studies reporting the follow-up time for each arm (7/16), the length of follow-up was similar (0-2-month difference) between the haplo-SCT and matched-SCT groups; however, follow-up differed by 8 to 12 months for 5 studies and by 25 to 40 months for 3 studies. One study enrolled only high-risk patients, 9 did not report the risk index status of the enrolled patients, and the remaining studies enrolled patients of some or all risk index statuses (low, intermediate, high).
The studies included in this systematic review and metaanalysis enrolled patients diagnosed with any hematological malignancies, the most common of which were AML (18 studies), myelodysplastic syndrome/myeloproliferative disorder (MDS; 15 studies), ALL (15 studies), and NHL (10 studies). Other conditions included HL (6 studies), CML (9 studies), myeloproliferative syndrome (4 studies), chronic lymphoid leukemia (4 studies), MM (4 studies), aplastic anemia (2 studies), and mixed phenotype acute leukemia (MPAL; 1 study). Eight studies focused on only a single condition, namely AML, ALL, CML, MDS, HL, or lymphoma.
Haplo-SCT was compared to a matched-SCT donated by a relative (MRD) in 11 studies or to a matched-SCT donated by a non-relative (MUD) in 6 studies. Seven studies compared haplo-SCT to matched-SCT from both MRDs and MUDs. Accordingly, the 24 studies made a total of 31 comparisons of haplo-SCT to matched-SCT; 18 were comparisons to a matched transplant from an MRD and 13 to a matched transplant from a MUD. While the use of MUDs versus MRDs was distributed fairly evenly among the included studies, the use of a conditioning regimen was less so, with less than half (10/24) using only a myeloablative ( As with the conditioning regimens, the studies displayed substantial variability regarding the source of donor stem cells. Patterns of use for either bone marrow (BM)-or peripheral blood (PB)-derived transplants fell into 6 categories: (1) the transplants were derived from only 1 source, either PB or BM, for 100% of patients (7 studies; MUD comparisons: 5; MRD comparisons: 5); (2) the transplants were derived from only 1 source for mostly all (>80%) of patients in both treatment arms (3 studies; MUD comparisons: 0; MRD comparisons: 3); (3) most transplants (>80%) were derived from BM for the haplo-SCT arm but most were derived from PB for the matched-SCT arm (5 studies; MUD comparisons: 2; MRD comparisons: 3); (4) the transplants were derived from only 1 source for mostly all patients (>80%) in one treatment arm but used a variable percentage of that source for patients in the other arm (6 studies; MUD comparisons: 6; MRD comparisons: 2); (5) the percentage of transplants derived from BM or PB were matched between the treatment arms, but neither source was used for a majority of patients (1 study; MUD comparisons: 0; MRD comparisons: 1); and (6) the percentage of transplants derived from BM or PB were not matched between the treatment arms (4 studies; MUD comparisons: 0; MRD comparisons: 4).
A summary of the primary outcomes of our study is presented in Table 2 . Several studies (9/24) reported the 1-, 3-, and 5-year rates of recurrence or relapse. The 1-year rates ranged from 3 to 37% in the haplo-SCT arms, 6 to 56% in the MRD arms, and 20 to 27% in the MUD arms; 3-year rates ranged from 5 to 52% in the haplo-SCT arms, 8 to 56% in the MRD arms, and 29 to 37% in the MUD arms; and 5-year rates ranged from 6 to 52% in the haplo-SCT arms, 11 to 56% in the MRD arms, and 28 to 39% in the MUD arms. The overall rates of grade II-IV acute GVHD, reported by 18 studies, ranged from 14 to 53% in the haplo-SCT arms, 13 to 50% in MRD arms, and 21 to 49% in the MUD arms. Rates of grade III-IV acute GVHD, reported by 18 studies, ranged from 2 to 30% in the haplo-SCT arms, 2 to 21% in MRD arms, and 3 to 25% in the MUD arms. Rates of chronic GVHD, reported by 19 studies, ranged from 13 to 85% in the haplo-SCT arms, 22 to 58% in MRD arms, and 22 to 69% in the MUD arms. Rates of overall non-relapse mortality, reported by 17 studies, ranged from 3 to 42% in the haplo-SCT arms, 8 to 31% in MRD arms, and 13 to 54% in the MUD arms.
Meta-analysis
Acute and chronic GVHD
Nineteen studies reported data for grade II-IV acute GVHD, 20 reported data for grade III-IV acute GVHD, and 21 reported data for chronic GVHD. The individual and pooled effects for these 3 outcomes are shown in a Forest plot in Fig. 2 . Significant heterogeneity existed for the included studies for grade II-IV acute GVHD (Q = 149.386, I 2 = 87.95%, P < 0.001), III-IV acute GVHD (Q = 36.387, I 2 = 47.78%, P = 0.009), and chronic GVHD (Q = 175.71, I 2 = 88.62%, P < 0.001); therefore, randomeffects models were used to determine the pooled effects. Our meta-analysis revealed no significant difference in the risk of grade II-IV acute GVHD, grade III-IV acute GVHD, or chronic GVHD between patients in the haplo-SCT groups and those in the matched-SCT groups (II-IV GVHD: pooled OR = 1.24, 95% CI = 0.86-1.77, P = 0.245; III-IV GVHD: pooled OR = 1.09, 95% CI = 0.84-1.40, P = 0.523; chronic GVHD: pooled OR = 0.73, 95% CI = 0.52-1.02, P = 0.068; Fig. 2a-c) .
In addition to calculating pooled effects for risk of GVHD for all patients, we compared the risk of developing GVHD for patients stratified by the type of matched-SCT (MUD or MRD), and by the type of conditioning regimen (MA or RIC). We also analyzed patients with acute leukemia as a subgroup. Our results are summarized in Table 3 . The risk of grade II-IV acute GVHD was significantly different for 3 of 5 subgroups. Among patients who received a matched-SCT from an MRD, the risk of grade II-IV acute GVHD was significantly less for patients who received a haplo-SCT than for patients who received a matched-SCT (pooled OR = 1.67, 95% CI = 1.09-2.57, P = 0.018). Among patients who received an MA regimen, risk of grade II-IV acute GVHD was also significantly less for patients in the haplo-SCT groups than for patients in the matched-SCT groups (pooled OR = 1.69, 95% CI = 1.04-2.74, P = 0.036). In contrast, the risk of grade II-IV acute GVHD was significantly higher for haplo-SCT patients who received an RIC regimen than for patients who received a matched-SCT and received RIC (pooled OR = 0.72, 95% CI = 0.60-0.88, P = 0.001). Risk of grade III-IV acute GVHD remained similar for 4 of 5 subgroups, but risk was significantly less for patients with acute leukemia who received a haplo-SCT than for patients who received a matched-SCT (pooled OR = 1.27, 95% CI = 1.04-1.55, P = 0.020). The risk of chronic GVHD was significantly different for 1 of 5 subgroups: among patients who received a matched-SCT from a MUD, those who received a haplo-SCT had significantly more risk than patients who received a matched-SCT (pooled OR = 0.60, 95% CI = 0.40-0.89, P = 0.012).
Non-relapse mortality
A total of 20 studies reported data for non-relapse mortality. The individual and pooled effects for this outcome are Reference number [52] shown in a forest plot in Fig. 3a . The studies displayed significant heterogeneity; therefore, we used a randomeffects model (Q = 102.26, I 2 = 81.42%, P < 0.001). The pooled effect indicated that patients in the two treatment groups had similar risks of non-relapse mortality (pooled OR = 0.92, 95% CI = 0.67-1.27, P = 0.619). The Fig. 2 A forest plot comparing a grade II-IV acute graft-versushost disease (GVHD), b grade III-IV acute GVHD, or c chronic GVHD of participants receiving haploidentical stem cell transplantation ("haplo-SCT") or matched allogeneic stem cell transplantation ("matched-SCT"). CI confidence interval difference in risk between treatment arms remained insignificant in the MUD, MRD, MA, and acute leukemia subgroups; however, patients in the RIC subgroup who received a haplo-SCT had significantly higher risk than did those who received a matched-SCT (pooled OR = 0.64, 95% CI = 0.42-0.97, P = 0.034; Table 3 ).
The 1-year CIR
Sixteen studies reported data for the 1-year CIR. The individual and pooled effects for this outcome are shown in a forest plot in Fig. 3b . Significant heterogeneity among the studies led us to use a random-effects model (heterogeneity test: Q = 37.406, I 2 = 59.90%, P = 0.001). The pooled effect revealed that haplo-SCT and matched-SCT were associated with similar risks of 1-year CIR (pooled OR = 1.00, 95% CI = 0.81-1.23, P = 1.000). Subgroup analysis revealed that the 1-year CIR remained similar among patients of the MRD, MA, RIC, and acute leukemia subgroups. However, for patients in the MUD subgroup, the risk of 1-year CIR was significantly less for patients who received a haplo-SCT than for patients who received a matched-SCT (pooled OR = 1.27, 95% CI = 1.09-1.47, P = 0.002; Table 3 ). 
Sensitivity analysis
Sensitivity analyses were performed by using the leave-oneout approach, in which the meta-analysis is performed with each study removed in turn. Our results are shown in Table 4 . The direction and magnitude of pooled estimates for grade II-IV acute GVHD, grade III-IV acute GVHD, non-relapse mortality, and 1-year CIR did not change significantly in direction or magnitude after the removal of any one study, indicating that the meta-analyses were robust. However, for chronic GVHD, when we removed the study of Wang et al. [52, 53] , Kanda et al. [42] , Luo et al. [44] , Chang et al. [35] , or Tomonari et al. [51] , the pooled OR became significant (P = 0.034, 0.026, 0.039, 0.031, and 0.024, respectively). Our data indicate that these studies may have had more influence on the pooled effect than did the others.
Publication bias
To evaluate the degree of study heterogeneity for each of the included studies, we constructed funnel plots, shown in Fig. 4 . The symmetry of the plots indicates no evidence of bias for grade II-IV acute GVHD (Fig. 4a) , grade III-IV acute GVHD (Fig. 4b) , chronic GVHD (Fig. 4c) , nonrelapse mortality (Fig. 4d) , or 1-year CIR (Fig. 4e) . We also examined the publication bias of the studies by using the QUIPS tool [29] . The results of this evaluation are shown in Fig. 5 . All of the 24 included studies had low risk of bias in 5 of the 6 study domains evaluated by QUIPS: study participation, study attrition, prognosis factor measurement, outcome measurement, and statistical analysis and reporting. For the remaining domain, confounding, 5 of the 24 studies had an unknown risk of bias (Fig. 5a) . Collectively, the QUIPS summary indicates that the quality of our meta-analysis is excellent, with very little risk of bias (Fig. 5b) . Drobyski (2002) Piemontese (2017) Bashey (2016) Bashey (2013) Gaballa (2016) Ghosh (2016) Kanda (2014) Wang (2016) 
Discussion
Hematological malignancies are among the most frequent cancers worldwide and mortality exceeds incidence for several types, including AML. Use of haplo-SCT to treat AML and other HMs has increased substantially over the past decade, but the decision to use haplo-SCT in many Reference number [52] countries may be based less on evidence of its superiority to matched-SCT than on the fact that it improves transplant accessibility for many patients, particularly non-Caucasians. For this reason, we compared the safety and efficacy of SCT from haploidentical donors to that of matched unrelated or related donors when treating hematological malignancies. Our analysis included 24 studies that enrolled a total of 11,359 patients. To our knowledge, this is among the first meta-analyses to compare the outcomes of haplo-SCT to those of matched-SCT from both related and unrelated donors. The included studies are of good quality and, just as importantly, almost all (83%) were published in the last 5 years. For these reasons, this report is an important update to the field.
Our results indicate that haplo-SCT performed similarly to matched-SCT for all primary endpoints that we examined: acute GVHD (grades II-IV and grades III-IV), chronic GVHD, non-relapse mortality, and 1-year CIR. However, when comparing haplo-SCT to matched-SCT from a MUD, we found that patients in the matched-SCT groups had a lower risk of chronic GVHD and a higher risk of 1-year CIR than did those in the haplo-SCT group. We also determined that patients who received an RIC regimen had better outcomes in the matched-SCT groups than in the haplo-SCT groups. Taken collectively, the data support the use of haplo-SCT as a safe and effective transplant option for patients when a matched donor is unavailable. We also suggest that matched-SCT should be the preferred option for patients who will undergo an RIC regimen.
The results of our meta-analysis are not in complete agreement with those of Chen et al. [55] who compared the outcomes of patients who received MA with either a haplo-SCT or a matched-SCT from a MRD. These authors suggest that matched-SCT should be preferred over haplo-SCT, because they found lower rates of platelet engraftment, higher risk of acute GVHD, and worse overall survival and disease-free survival among the haplo-SCT groups. However, the haplo-SCT groups had a lower relapse rate and similar rates of neutrophil engraftment, chronic GVHD, and transplant-related mortality. The study by Chen et al. [55] assessed 7 studies, 4 of which were included in our metaanalysis, that enrolled a total population of 1919 patients. We suspect that our larger population of over 11,000 patients allowed us to determine more accurate pooled effects for acute GVHD and relapse-related mortality. However, future meta-analyses should try to determine if matched-SCT does provide any survival advantage over haplo-SCT.
The fact that this meta-analysis is one of only a few to compare the outcomes of haplo-SCT to those of matched-SCT highlights current shortcomings in the literature. First, there is a lack of evidence to guide practitioners when trying to choose between a more readily available haploidentical . The x-axis shows the log-odds ratio of the pooled effect; the yaxis shows precision. Each circle represents one of the included studies donor or a matched unrelated donor. The most recent guidelines of the American Society for Blood and Marrow Transplantation did not specify a preferred donor source for HSCT [56] . Guidelines of the British Society for Blood and Marrow Transplantations (BSBMT) refer to the suitability of haplo-SCT for lymphoma [57] , while those of the European Society for Blood and Marrow Transplantation (EBMT) mention haplo-SCT for leukemias but not lymphomas [58] . This variability and lack of specificity may be expected given the historically limited availability of donors. However, the number of volunteers registered in the international Be The Match Registry of the National Marrow Donor Program is on the rise, currently at 13.5 million [59] . Moreover, since Drobyski et al. [38] China over the past 5 to 10 years, and levels are currently below that of haplo-SCT [7, 8] , although the same may not be true in the United States [26] . Therefore, future research should be aligned with trends identified by large national and international organizations like the EBMT and the Center for International Blood and Marrow Transplant Research.
Our meta-analysis has revealed that risk of chronic GVHD is similar for patients who received a haplo-SCT than for those who receive a matched-SCT. Given that GVHD results at least partly from the presence of recipient T cells [60] , it is important to determine if the included studies used T-cell depletion to minimize risk of chronic GVHD. The majority of studies (19 of 23) used unmanipulated (T-cell replete) grafts for 100% of patients. All of the patients in the study by Drobyski et al. [38] received Tcell-depleted grafts, while Piemontese et al. [47] reported that almost half of haplo-SCT patients received a T-celldepleted graft. Alternative methods were evaluated by Luo et al. [44] , who used T-cell-replete haplo-SCT but administered a low dose of anti-T-lymphocyte globulin, and by Gaballa et al. [39] , who used CD3+ and CD34+-selected infusions separated by a cyclophosphamide regimen. This distribution indicates not only that the practice of T-cellreplete haplo-SCT has advanced enough to yield outcomes similar to that of matched-SCT, but also the ongoing difficulty in managing graft rejection for patients with HMs. We should also note that most of the included studies used post-transplant cyclophosphamide treatment to decrease the risk of GVHD. A recent meta-analysis by Gu et al. [61] supports the idea that use of a cyclophosphamide regimen can help reduce the risk of chronic GVHD among patients who receive haplo-SCT. Their case-control study of over 2000 patients revealed that the incidence of moderate to severe chronic GVHD was significantly lower for patients who received post-transplant cyclophosphamide after a haplo-SCT than it was for patients who received a matched-SCT from an MRD [61] .
Although our overall analysis found similar risks for chronic GVHD, our subgroup analyses indicated that patients in the haplo-SCT group had a higher risk of chronic GVHD than did those who receive a matched-SCT from a MUD. At present, we are uncertain of the reasons for this result. Interestingly, the patients in the MUD subgroup had high proportions of PB-derived transplants, while those in the haplo-SCT group had high proportions of BM-derived transplants. Some recent studies of both haplo-SCT and matched-SCT have found that PB-derived transplants were associated with higher incidences and risk of chronic GVHD than were transplants derived from bone marrow stem cells [62] [63] [64] [65] [66] . Future studies should perform more extensive comparisons of PB-and BM-derived transplants from haploidentical donors.
This study had some limitations. First, we acknowledge that most of the studies included in our analysis enrolled patients with various types of HM. With the exception of acute leukemia, we did not stratify by type of HM because of an insufficient number of patients in each subgroup. As a result, our findings should be interpreted with some caution. Second, the studies we evaluated were either a prospective cohort study or a retrospective study. As no randomized controlled trials were included, the level of evidence is moderate. Third, the possibility of center bias should be considered in this meta-analysis, because the lack of availability of a matched donor for many patients might predicate the need for a transplant from a mismatched donor. Finally, this meta-analysis did not compare the risks and benefits of haplo-SCT to those of umbilical cord blood transplantation (UCBT). This was beyond the scope of our meta-analysis but should be an important goal of future research.
In conclusion, we compared the safety and efficacy of SCT from haploidentical donors to that of matched unrelated or related donors when treating hematological malignancies. Our results indicate that haplo-SCT should continue to be considered as a safe and effective transplant option for patients when a matched donor is unavailable. We also suggest that matched-SCT should be the preferred option for patients who will undergo an RIC regimen. Future studies should stratify patients with each type of HM to determine if haplo-SCT would be a disadvantage for some patients. Moreover, the field could benefit from a comparison of the outcomes of haplo-SCT and UCBT.
